Black Diamond Therapeutics (BDTX) Stock Overview
A clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BDTX Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Black Diamond Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.95 |
| 52 Week High | US$6.75 |
| 52 Week Low | US$1.20 |
| Beta | 2.72 |
| 1 Month Change | 27.71% |
| 3 Month Change | 116.91% |
| 1 Year Change | -52.50% |
| 3 Year Change | -10.33% |
| 5 Year Change | -89.85% |
| Change since IPO | -92.53% |
Recent News & Updates
Recent updates
Black Diamond Therapeutics: Targeted Approach And Early Efficacy Signals Create Potential For Significant Upside
Jun 10We Think Black Diamond Therapeutics (NASDAQ:BDTX) Needs To Drive Business Growth Carefully
May 04
Black Diamond Therapeutics Trades Well Below Cash After Lucrative Deal With Servier
Mar 25Black Diamond Therapeutics: In Decline, But Why?
Mar 13Black Diamond Therapeutics: Speculative Buy With Precision Oncology Catalysts
Dec 30We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate
Oct 30Black Diamond: EGFRm NSCLC Targeting Continues With Q1 Of 2025 Data
Oct 08Black Diamond: High-Risk, High-Reward, Low-Profile EGFR Inhibitor Worth A Deep Dive
Jun 27Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?
May 21We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate
Jan 31Black Diamond Therapeutics: Emerging Data In EGFR-Mutant NSCLC And GBM
Jan 12Here's Why We're Watching Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Situation
Oct 26Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?
May 05We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate
Jan 16Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Invest In Growth?
Oct 02Will Black Diamond Therapeutics (NASDAQ:BDTX) Spend Its Cash Wisely?
Jul 02We Think Black Diamond Therapeutics (NASDAQ:BDTX) Needs To Drive Business Growth Carefully
Jan 16We're Hopeful That Black Diamond Therapeutics (NASDAQ:BDTX) Will Use Its Cash Wisely
Jun 11We're Not Very Worried About Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate
Feb 26Shareholder Returns
| BDTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 18.0% | 0.4% | 0.2% |
| 1Y | -52.5% | -14.8% | 10.0% |
Return vs Industry: BDTX underperformed the US Biotechs industry which returned -11.2% over the past year.
Return vs Market: BDTX underperformed the US Market which returned 11.4% over the past year.
Price Volatility
| BDTX volatility | |
|---|---|
| BDTX Average Weekly Movement | 10.5% |
| Biotechs Industry Average Movement | 11.4% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: BDTX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BDTX's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 24 | Mark Velleca | www.blackdiamondtherapeutics.com |
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company’s lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial.
Black Diamond Therapeutics, Inc. Fundamentals Summary
| BDTX fundamental statistics | |
|---|---|
| Market cap | US$167.18m |
| Earnings (TTM) | US$5.09m |
| Revenue (TTM) | US$70.00m |
Is BDTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BDTX income statement (TTM) | |
|---|---|
| Revenue | US$70.00m |
| Cost of Revenue | US$0 |
| Gross Profit | US$70.00m |
| Other Expenses | US$64.91m |
| Earnings | US$5.09m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.09 |
| Gross Margin | 100.00% |
| Net Profit Margin | 7.27% |
| Debt/Equity Ratio | 0% |
How did BDTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/15 13:09 |
| End of Day Share Price | 2025/07/15 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Black Diamond Therapeutics, Inc. is covered by 13 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhiqiang Shu | Berenberg |
| Arlinda Lee | Canaccord Genuity |
| Robert Burns | H.C. Wainwright & Co. |